FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113092110> ?p ?o ?g. }

• W2113092110 endingPage "635" @default.
• W2113092110 startingPage "626" @default.
• W2113092110 abstract "Noncirrhotic portal hypertension (NCPH) is a newly described life-threatening liver disease of unknown cause in human immunodeficiency virus (HIV)-infected persons. Postulated pathogenesis includes prolonged exposure to antiretroviral therapy, particularly didanosine.We performed a nested case-control study including 15 patients with NCPH and 75 matched control subjects of the Swiss HIV Cohort Study to investigate risk factors for the development of NCPH. Matching criteria were similar duration of HIV infection, absence of viral hepatitis, and follow-up to at least the date of NCPH diagnosis in the respective case.All 15 case patients had endoscopically documented esophageal varices and absence of liver cirrhosis on biopsies; 4 died because of hepatic complications. At NCPH diagnosis, case patients and control subjects were similar concerning sex; race; Centers for Disease Control and Prevention stage; HIV-RNA level; CD4 cell count nadir; and lipids and lipodystrophy. Differences were found in age (conditional logistic regression odds ratio [OR] for 10 years older, 2.9; 95% confidence interval [CI], 1.4-6.1); homosexuality (OR, 4.5; 95% CI, 1.2-17); current CD4 cell count <200 cells/microL (OR, 34.3; 95% CI, 4.3-277); diabetes mellitus (OR, 8.8; 95% CI, 1.6-49); alanine aminotransferase level higher than normal (OR, 13.0; 95% CI, 2.7-63); alkaline phosphatase higher than normal (OR, 18.3; 95% CI, 4.0-85); and platelets lower than normal (OR, 20.5; 95% CI, 2.4-178). Cumulative exposure to antiretroviral therapy (OR per year, 1.3; 95% CI, 1.0-1.6), nucleoside reverse-transcriptase inhibitor (OR, 1.3; 95% CI, 1.1-1.7), didanosine (OR, 3.4; 95% CI, 1.5-8.1), ritonavir (OR, 1.4; 95% CI, 1.0-1.9), and nelfinavir (OR, 1.4; 95% CI, 1.0-1.9) were longer in case patients. Exposure to nonnucleoside reverse-transcriptase inhibitor and other protease inhibitors were not different between groups. In bivariable models, only the association of NCPH with didanosine exposure was robust; other covariables were not independent risk factors.We found a strong association between prolonged exposure to didanosine and the development of NCPH." @default.
• W2113092110 created "2016-06-24" @default.
• W2113092110 creator A5002404548 @default.
• W2113092110 creator A5011677217 @default.
• W2113092110 creator A5011959232 @default.
• W2113092110 creator A5020344258 @default.
• W2113092110 creator A5028829460 @default.
• W2113092110 creator A5032116605 @default.
• W2113092110 creator A5036232178 @default.
• W2113092110 creator A5039985712 @default.
• W2113092110 creator A5075603706 @default.
• W2113092110 creator A5078674653 @default.
• W2113092110 date "2009-08-15" @default.
• W2113092110 modified "2023-10-16" @default.
• W2113092110 title "Association of Noncirrhotic Portal Hypertension in HIV‐Infected Persons and Antiretroviral Therapy with Didanosine: A Nested Case‐Control Study" @default.
• W2113092110 cites W1426208733 @default.
• W2113092110 cites W1536347875 @default.
• W2113092110 cites W1573558157 @default.
• W2113092110 cites W1969356397 @default.
• W2113092110 cites W1975222878 @default.
• W2113092110 cites W1975619234 @default.
• W2113092110 cites W2015386493 @default.
• W2113092110 cites W2015727972 @default.
• W2113092110 cites W2020659644 @default.
• W2113092110 cites W2022542927 @default.
• W2113092110 cites W2028338365 @default.
• W2113092110 cites W2030020525 @default.
• W2113092110 cites W2032944154 @default.
• W2113092110 cites W2039053942 @default.
• W2113092110 cites W2047358558 @default.
• W2113092110 cites W2050385934 @default.
• W2113092110 cites W2063820308 @default.
• W2113092110 cites W2067311378 @default.
• W2113092110 cites W2075030594 @default.
• W2113092110 cites W2078128757 @default.
• W2113092110 cites W2084280844 @default.
• W2113092110 cites W2095823426 @default.
• W2113092110 cites W2107732097 @default.
• W2113092110 cites W2143073805 @default.
• W2113092110 cites W2171520428 @default.
• W2113092110 cites W2186710178 @default.
• W2113092110 cites W2318289184 @default.
• W2113092110 cites W2320121177 @default.
• W2113092110 cites W2334729165 @default.
• W2113092110 cites W2418571731 @default.
• W2113092110 cites W2570113386 @default.
• W2113092110 cites W83931366 @default.
• W2113092110 doi "https://doi.org/10.1086/603559" @default.
• W2113092110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19589079" @default.
• W2113092110 hasPublicationYear "2009" @default.
• W2113092110 type Work @default.
• W2113092110 sameAs 2113092110 @default.
• W2113092110 citedByCount "117" @default.
• W2113092110 countsByYear W21130921102012 @default.
• W2113092110 countsByYear W21130921102013 @default.
• W2113092110 countsByYear W21130921102014 @default.
• W2113092110 countsByYear W21130921102015 @default.
• W2113092110 countsByYear W21130921102016 @default.
• W2113092110 countsByYear W21130921102017 @default.
• W2113092110 countsByYear W21130921102018 @default.
• W2113092110 countsByYear W21130921102019 @default.
• W2113092110 countsByYear W21130921102020 @default.
• W2113092110 countsByYear W21130921102021 @default.
• W2113092110 countsByYear W21130921102022 @default.
• W2113092110 countsByYear W21130921102023 @default.
• W2113092110 crossrefType "journal-article" @default.
• W2113092110 hasAuthorship W2113092110A5002404548 @default.
• W2113092110 hasAuthorship W2113092110A5011677217 @default.
• W2113092110 hasAuthorship W2113092110A5011959232 @default.
• W2113092110 hasAuthorship W2113092110A5020344258 @default.
• W2113092110 hasAuthorship W2113092110A5028829460 @default.
• W2113092110 hasAuthorship W2113092110A5032116605 @default.
• W2113092110 hasAuthorship W2113092110A5036232178 @default.
• W2113092110 hasAuthorship W2113092110A5039985712 @default.
• W2113092110 hasAuthorship W2113092110A5075603706 @default.
• W2113092110 hasAuthorship W2113092110A5078674653 @default.
• W2113092110 hasBestOaLocation W21130921102 @default.
• W2113092110 hasConcept C126322002 @default.
• W2113092110 hasConcept C142462285 @default.
• W2113092110 hasConcept C146304588 @default.
• W2113092110 hasConcept C156957248 @default.
• W2113092110 hasConcept C165617652 @default.
• W2113092110 hasConcept C203014093 @default.
• W2113092110 hasConcept C2777447569 @default.
• W2113092110 hasConcept C2993143319 @default.
• W2113092110 hasConcept C3013748606 @default.
• W2113092110 hasConcept C44249647 @default.
• W2113092110 hasConcept C71924100 @default.
• W2113092110 hasConcept C90924648 @default.
• W2113092110 hasConceptScore W2113092110C126322002 @default.
• W2113092110 hasConceptScore W2113092110C142462285 @default.
• W2113092110 hasConceptScore W2113092110C146304588 @default.
• W2113092110 hasConceptScore W2113092110C156957248 @default.
• W2113092110 hasConceptScore W2113092110C165617652 @default.
• W2113092110 hasConceptScore W2113092110C203014093 @default.
• W2113092110 hasConceptScore W2113092110C2777447569 @default.
• W2113092110 hasConceptScore W2113092110C2993143319 @default.
• W2113092110 hasConceptScore W2113092110C3013748606 @default.

• next